Business
Novo Nordisk shares plunge 7% as 2030 growth plan disappoints investors
Stock market responds with sharp sell-off reaching 7.7% decline
2 Sep 21 4:31 AM · 5d ago · 2 articles · 1 source · development 2 of 5
Novo Nordisk shares fell as much as 7.7% in Copenhagen trading following the capital markets day announcement. By mid-morning, shares had recovered slightly to down 4.2% but remained significantly lower than opening.
“The weight-loss drug manufacturer failed to excite investors hoping for a turnaround.”
Jaimy Lee, MarketWatch reporter · rss ↗Novo Nordisk Danish pharmaceutical company
Mike Doustdar Novo Nordisk Chief Executive OfficerEli Lilly & Co. Rival pharmaceutical company
The whole story articlesposts the bright band is this development · numbered dots are the others · click one to jump
Sep 22Sep 23Sep 24yesterdaynow · 3:16 PM ET
What was reported 1 claim about this development
-
1 outlet Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
first by CNBC, 5d ago
All 5 developments of Novo Nordisk shares plunge 7% as 2030 growth plan… →
NewswiresMastodonGoogle News